CEO Vas Narasimhan recently told investors Novartis is well along toward its goal of consolidating its manufacturing into one “that’s much more focused on high-end technologies.”
One of the facilities that is in the path of that advancement is the company’s Grimsby, U.K. operation where about 400 workers are set to lose their jobs unless a buyer can be found for the site.
Taskforce members made up of workers, local officials and Novartis met today for an update on how the closing process will proceed if a buyer does not materialize, BusinessLive reports. The task force was formed to aid workers and the town with job losses after the closing was first announced in 2018.
Novartis last fall said half-a-dozen companies had sized up the site for a possible purchase but nothing has been announced since.
Novartis intends to begin layoffs in April with the closure of one facility at the site and wind down the rest of the operation by the end of the year.
A site in Ireland is also being downsized. The drugmaker announced in the fall that it will close a production facility at the Ringaskiddy site in Ireland by mid-2022 as it consolidates its active pharmaceutical ingredient operations there.
Novartis has been closing and selling off bulk and formulation manufacturing facilities as it shifts to high-margin specialized drugs like cell and gene therapies and away from older meds and generics.
“We also are advancing our efforts in procurement and manufacturing, and are really reducing the excess inventories that we’re holding and also deploying data and digital much more aggressively across the manufacturing network,” Narasimhan said on an earnings call two weeks ago.
By Eric Palmer
Source: Fierce Pharma
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.